| P50 | author | Karla D Passalacqua | Q41671776 |
| P2093 | author name string | Timothy D Read | |
| | Emily K Crispell | |
| | Sarah W Satola | |
| P2860 | cites work | Regulation of hemolysin expression and virulence of Staphylococcus aureus by a serine/threonine kinase and phosphatase | Q21136345 |
| | The COG database: an updated version includes eukaryotes | Q21284294 |
| | Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic | Q24614464 |
| | The skin microbiome | Q24634180 |
| | Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications | Q24646677 |
| | Rapid and simple comparison of messenger RNA levels using real-time PCR. | Q25257674 |
| | Solution structure of the parvulin-type PPIase domain of Staphylococcus aureus PrsA – Implications for the catalytic mechanism of parvulins | Q27654271 |
| | Crystal Structure of Staphylococcus aureus Metallopeptidase (Sapep) Reveals Large Domain Motions between the Manganese-bound and Apo-states | Q27663269 |
| | A genomic perspective on protein families | Q27860913 |
| | Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus | Q28300379 |
| | Interplay in the selection of fluoroquinolone resistance and bacterial fitness | Q28475870 |
| | Whole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureus | Q28478770 |
| | An alternate conformation and a third metal in PstP/Ppp, the M. tuberculosis PP2C-Family Ser/Thr protein phosphatase | Q28486667 |
| | Bacterial community variation in human body habitats across space and time | Q29547432 |
| | Fast algorithms for large-scale genome alignment and comparison | Q29618357 |
| | Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus | Q29619365 |
| | Staphylococcus aureus expresses a cell surface protein that binds both IgG and beta2-glycoprotein I. | Q30671163 |
| | A second IgG-binding protein in Staphylococcus aureus | Q32064577 |
| | Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin | Q33233009 |
| | Exploring glycopeptide-resistance in Staphylococcus aureus: a combined proteomics and transcriptomics approach for the identification of resistance-related markers. | Q33264418 |
| | Subtle genetic changes enhance virulence of methicillin resistant and sensitive Staphylococcus aureus | Q33305151 |
| | Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia | Q33321447 |
| | Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. | Q33613735 |
| | Methicillin-resistant Staphylococcus aureus endocarditis and de novo development of daptomycin resistance during therapy | Q42656550 |
| | Structure and complexity of a bacterial transcriptome. | Q42841193 |
| | Penicillin-binding protein folding is dependent on the PrsA peptidyl-prolyl cis-trans isomerase in Bacillus subtilis | Q43058422 |
| | Extended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant Staphylococcus aureus | Q43091444 |
| | Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years | Q43117809 |
| | Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility | Q43433837 |
| | Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus | Q43579575 |
| | Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance | Q44144059 |
| | Impact of USA300 methicillin-resistant Staphylococcus aureus on clinical outcomes of patients with pneumonia or central line-associated bloodstream infections | Q44422021 |
| | Identification of the first vancomycin intermediate-resistant Staphylococcus aureus (VISA) isolate from a hospital in Portugal | Q44837920 |
| | Nucleotide substitutions in Staphylococcus aureus strains, Mu50, Mu3, and N315. | Q44894963 |
| | Occurrence of a USA300 vancomycin-intermediate Staphylococcus aureus | Q46325792 |
| | Comparative proteomics analyses reveal a potential biomarker for the detection of vancomycin-intermediate Staphylococcus aureus strains | Q46903914 |
| | Structure-function analysis of PrsA reveals roles for the parvulin-like and flanking N- and C-terminal domains in protein folding and secretion in Bacillus subtilis. | Q51026793 |
| | Staphylococcal coagulase; mode of action and antigenicity. | Q51043511 |
| | Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus. | Q51580715 |
| | Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 |
| | Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure | Q33756688 |
| | Staphylococcus aureus deficient in lipidation of prelipoproteins is attenuated in growth and immune activation | Q33769293 |
| | The Staphylococcus aureus RNome and its commitment to virulence | Q33851489 |
| | Waves of resistance: Staphylococcus aureus in the antibiotic era. | Q33854398 |
| | A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates | Q33981239 |
| | Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin | Q34107062 |
| | Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary | Q34158152 |
| | Complete nucleotide sequence analysis of plasmids in strains of Staphylococcus aureus clone USA300 reveals a high level of identity among isolates with closely related core genome sequences | Q34433256 |
| | Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing | Q34630593 |
| | Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. | Q34751827 |
| | Role of the accessory gene regulator agr in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. | Q34931778 |
| | Host defenses against Staphylococcus aureus infection require recognition of bacterial lipoproteins | Q35025079 |
| | Heterogeneous vancomycin-intermediate susceptibility in a community-associated methicillin-resistant Staphylococcus aureus epidemic clone, in a case of Infective Endocarditis in Argentina | Q35035275 |
| | The Sbi protein is a multifunctional immune evasion factor of Staphylococcus aureus | Q35191984 |
| | Post-translocational folding of secretory proteins in Gram-positive bacteria | Q35951996 |
| | The posttranslocational chaperone lipoprotein PrsA is involved in both glycopeptide and oxacillin resistance in Staphylococcus aureus | Q36086420 |
| | Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 |
| | Modulation of cell wall structure and antimicrobial susceptibility by a Staphylococcus aureus eukaryote-like serine/threonine kinase and phosphatase | Q37144963 |
| | The first vancomycin-intermediate Staphylococcus aureus strains isolated from patients in Thailand | Q37256413 |
| | Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions | Q37602845 |
| | The impact of serine/threonine phosphorylation in Staphylococcus aureus | Q37604056 |
| | Antibiotic resistance and its cost: is it possible to reverse resistance? | Q37704177 |
| | Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature | Q37824612 |
| | Eukaryote-like serine/threonine kinases and phosphatases in bacteria | Q37849482 |
| | Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus | Q40166227 |
| | Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus | Q41840194 |
| | Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis | Q41847174 |
| | Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus | Q41855274 |
| | An RpoB Mutation Confers Dual Heteroresistance to Daptomycin and Vancomycin in Staphylococcus aureus | Q41902616 |
| | Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. | Q41912284 |
| | Differential target gene activation by the Staphylococcus aureus two-component system saeRS. | Q41989725 |
| | walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. | Q42110968 |
| | Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus | Q42111680 |
| | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. | Q42111733 |
| | Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. | Q42112490 |
| | Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus | Q42119436 |
| | Failure of Vancomycin Continuous Infusion against Experimental Endocarditis Due to Vancomycin-Intermediate Staphylococcus aureus | Q42147280 |
| | Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method | Q42169334 |
| | The protein phosphatase 2C (PP2C) superfamily: detection of bacterial homologues. | Q42247167 |
| | spa typing for epidemiological surveillance of Staphylococcus aureus | Q42624365 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | RNA sequencing | Q2542347 |
| | Staphylococcus aureus | Q188121 |
| | vancomycin | Q424027 |
| P1104 | number of pages | 12 | |
| P304 | page(s) | 5212-5223 | |
| P577 | publication date | 2012-07-30 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin | |
| P478 | volume | 56 | |